ArticleOncotarget2017
Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines.Prostate cancer · 2026Article
- Transcriptomic Profile of Perineural Invasion in Prostate Cancer Identifies Prognostic Gene Signatures.Biomedicines · 2025Article
- A novel approach to engineering three-dimensional bladder tumor models for drug testing.Scientific reports · 2024Article
- Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer.International journal of molecular sciences · 2024Article
- Histologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate Cancer.Cancers · 2024Article
- Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.Discover oncology · 2023Article
- Role of Metabolism and Metabolic Pathways in Prostate Cancer.Metabolites · 2023Review
- Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.Biomolecules · 2022Review
- Review
- The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer.BMC medical genomics · 2021Article
- Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery.Journal of the Endocrine Society · 2020Review
- Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer.Biomolecules · 2020Review
- Review
- Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification.Oncotarget · 2018Review
- Future Perspectives and Challenges of Prostate MR Imaging.Radiologic clinics of North America · 2018Review
- Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases.Oncogene · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To avoid over- or under-treatment of primary prostate tumours, there is a critical need for molecular signatures to discriminate indolent from aggressive, lethal disease. Reprogrammed energy metabolism is an important hallmark of cancer, and abnormal metabolic characteristics of cancers have been implicated as potential diagnostic/prognostic signatures. While genomic and transcriptomic heterogeneity of prostate cancer is well documented and associated with tumour progression, less is known about metabolic heterogeneity of the disease. Using a panel of high fidelity patient-derived xenograft (PDX) models derived from hormone-naïve prostate cancer, we demonstrated heterogeneity of expression of genes involved in cellular energetics and macromolecular biosynthesis. Such heterogeneity was also observed in clinical, treatment-naïve prostate cancers by analyzing the transcriptome sequencing data. Importantly, a metabolic gene signature of increased one-carbon metabolism or decreased proline degradation was identified to be associated with significantly decreased biochemical disease-free patient survival. These results suggest that metabolic heterogeneity of hormone-naïve prostate cancer is of biological and clinical importance and motivate further studies to determine the heterogeneity in metabolic flux in the disease that may lead to identification of new signatures for tumour/patient stratification and the development of new strategies and targets for therapy of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.